Avadel Pharmaceuticals (AVDL) Cash from Operations: 2015-2022
Historic Cash from Operations for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Dec 2022 value amounting to -$15.4 million.
- Avadel Pharmaceuticals' Cash from Operations rose 31.72% to -$15.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$70.3 million, marking a year-over-year increase of 9.06%. This contributed to the annual value of -$46.9 million for FY2024, which is 63.50% up from last year.
- According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Cash from Operations is -$15.4 million, which was down 125.87% from -$6.8 million recorded in Q3 2022.
- In the past 5 years, Avadel Pharmaceuticals' Cash from Operations registered a high of -$1.4 million during Q2 2019, and its lowest value of -$34.0 million during Q1 2022.
- For the 3-year period, Avadel Pharmaceuticals' Cash from Operations averaged around -$16.4 million, with its median value being -$14.7 million (2022).
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 562.13% in 2018, then spiked by 92.74% in 2019.
- Over the past 5 years, Avadel Pharmaceuticals' Cash from Operations (Quarterly) stood at -$24.5 million in 2018, then skyrocketed by 66.35% to -$8.3 million in 2019, then slumped by 131.73% to -$19.1 million in 2020, then declined by 17.68% to -$22.5 million in 2021, then skyrocketed by 31.72% to -$15.4 million in 2022.
- Its last three reported values are -$15.4 million in Q4 2022, -$6.8 million for Q3 2022, and -$14.1 million during Q2 2022.